Posted by Michael Wonder on 21 Oct 2020
Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China
21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Guangzhou Healthquest Pharma, a wholly owned subsidiary of the company, priority review to its new drug application for Olverembatinib (HQP1351).
The application of olverembatinib was submitted based on results from two pivotal studies for the treatment of patients resistant to tyrosine kinase inhibitors and with T315I mutant chronic phase chronic myeloid leukaemia and accelerated phase chronic myeloid leukaemia.
